Clinical Spectrum of Hereditary Tyrosinemia Type 1 in a Cohort of Pakistani Children

Overview

Journal Clin Med Insights Pediatr

Publisher Sage Publications

Specialty Pediatrics

Date 2024 Mar 8

PMID 38456192

Authors

Sabeen Abid Khan

Misbah Fakih

Nida Taufiq

Afaaf Ahmerin

Asfand Bangash

Munir Iqbal Malik

Affiliations

Soon will be listed here.

Abstract

Background: Hereditary Tyrosinemia Type 1 (HT1), a rare autosomal recessive metabolic disorder, arises from fumarylacetoacetate (FAH) enzyme deficiency, resulting in toxic metabolite buildup. It manifests in acute, subacute, and chronic forms, with early diagnosis and Nitisinone treatment being vital.

Objectives: The study aims to highlight the different clinical presentations of Hereditary Tyrosinemia type 1 in a cohort of Pakistani children.

Design: Retrospective observational study.

Methodology: All patients diagnosed with HT1 at Shifa International Hospital, Islamabad and Pak Emirates Military Hospital, Rawalpindi between 2010 and 2023 were included. Information was collected regarding age, gender, symptoms, physical signs, and laboratory results.

Results: The study identified 6 cases of HT1. The average age at presentation was 8 months, with a mean delay in diagnosis of 26.8 months. Males were 4 (66.7%) and 2 (33.3%) were females. All patients had underlying liver disease presenting as abdominal distension with hepatosplenomegaly and accompanying growth failure. Four cases presented with rickets, 2 of which had hypophosphatemic rickets. Urine for succinylacetone was raised in all patients. Alpha fetoprotein was raised but hepatocellular carcinoma was diagnosed in 1 patient only. Low protein diet, and vitamin supplements were used for management. Five of the 6 patients died within 2 years of diagnosis.

Conclusion: Delayed referrals and unavailability of Nitisinone are the major challenges in diagnosing and treating HT1 in Pakistan.

References

Arnon R, Annunziato R, Miloh T, Wasserstein M, Sogawa H, Wilson M . Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database. Pediatr Transplant. 2011; 15(4):400-5. DOI: 10.1111/j.1399-3046.2011.01497.x. View

Hajji H, Imbard A, Spraul A, Taibi L, Barbier V, Habes D . Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening. Mol Genet Metab Rep. 2022; 33:100933. PMC: 9649935. DOI: 10.1016/j.ymgmr.2022.100933. View

Chinsky J, Singh R, Ficicioglu C, van Karnebeek C, Grompe M, Mitchell G . Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017; 19(12). PMC: 5729346. DOI: 10.1038/gim.2017.101. View

Bartlett D, Lloyd C, McKiernan P, Newsome P . Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis. 2014; 37(5):745-52. DOI: 10.1007/s10545-014-9683-x. View

Dweikat I, Qawasmi N, Najeeb A, Radwan M . Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1. Metabol Open. 2021; 9:100083. PMC: 7868710. DOI: 10.1016/j.metop.2021.100083. View

Yilmaz O, Daly A, Pinto A, Ashmore C, Evans S, Gupte G . Physical Growth of Patients with Hereditary Tyrosinaemia Type I: A Single-Centre Retrospective Study. Nutrients. 2021; 13(9). PMC: 8472760. DOI: 10.3390/nu13093070. View

De Laet C, Dionisi-Vici C, Leonard J, McKiernan P, Mitchell G, Monti L . Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013; 8:8. PMC: 3558375. DOI: 10.1186/1750-1172-8-8. View

Arora N, Stumper O, Wright J, Kelly D, McKiernan P . Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis. 2006; 29(1):54-7. DOI: 10.1007/s10545-006-0203-5. View

Brito Dos Santos S, Bertholet-Thomas A, Butin M, Dubourg L, Fouilhoux A, Bacchetta J . Tyrosinemia type 1 in pediatric nephrology: Not always straightforward. Arch Pediatr. 2021; 28(4):338-341. DOI: 10.1016/j.arcped.2021.03.002. View

10.

Kitagawa T . Hepatorenal tyrosinemia. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88(5):192-200. PMC: 3410490. DOI: 10.2183/pjab.88.192. View

11.

Couce M, Dalmau J, Del Toro M, Pintos-Morell G, Aldamiz-Echevarria L . Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int. 2011; 53(6):985-9. DOI: 10.1111/j.1442-200X.2011.03427.x. View

12.

Aktuglu-Zeybek A, Kiykim E, Cansever M . Hereditary Tyrosinemia Type 1 in Turkey. Adv Exp Med Biol. 2017; 959:157-172. DOI: 10.1007/978-3-319-55780-9_15. View

13.

Angileri F, Bergeron A, Morrow G, Lettre F, Gray G, Hutchin T . Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1. JIMD Rep. 2015; 19:43-58. PMC: 4501228. DOI: 10.1007/8904_2014_363. View

14.

van Ginkel W, Jahja R, Huijbregts S, van Spronsen F . Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients. Adv Exp Med Biol. 2017; 959:111-122. DOI: 10.1007/978-3-319-55780-9_10. View

15.

Baumann U, Preece M, Green A, Kelly D, McKiernan P . Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis. 2005; 28(2):131-5. DOI: 10.1007/s10545-005-5517-1. View

16.

Shah I, Shah F . Tyrosinemia type I: Case series with response to treatment to NTBC. Indian J Gastroenterol. 2016; 35(3):229-31. DOI: 10.1007/s12664-016-0650-3. View

17.

Bijarnia S, Puri R, Ruel J, Gray G, Jenkinson L, Verma I . Tyrosinemia type I--diagnostic issues and prenatal diagnosis. Indian J Pediatr. 2006; 73(2):163-5. DOI: 10.1007/BF02820214. View

18.

Daou K, Barhoumi A, Bassyouni A, Karam P . Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review. Front Pediatr. 2021; 9:698577. PMC: 8377248. DOI: 10.3389/fped.2021.698577. View

19.

van Ginkel W, Pennings J, van Spronsen F . Liver Cancer in Tyrosinemia Type 1. Adv Exp Med Biol. 2017; 959:101-109. DOI: 10.1007/978-3-319-55780-9_9. View

20.

Alobaidy H, Barkaoui E . Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya. Iran J Pediatr. 2015; 25(5):e3608. PMC: 4610339. DOI: 10.5812/ijp.3608. View